NCT01848236

Brief Summary

We would like to determine if vitamin D insufficiency exists in different ethnic groups, if it has an effect on bone mass and muscle function, if it has an impact on the function of the cells of the immune system, and if the functioning level of these systems can be improved by stabilizing the vitamin D levels to within normal limits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

May 2, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 7, 2013

Completed
6.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

March 3, 2020

Status Verified

February 1, 2020

Enrollment Period

9.5 years

First QC Date

May 2, 2013

Last Update Submit

February 28, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in serum 25D

    5 weeks

Secondary Outcomes (8)

  • Change in bone mineral density by biochemistry

    5 weeks

  • Change in muscle strength by exam

    5 weeks

  • Change in muscle strength by questionnaire

    5 weeks

  • Change in bone mineral density by DXA scan

    5 weeks

  • Change in fractional urinary calcium:creatinine excretion ratio

    5 weeks

  • +3 more secondary outcomes

Study Arms (2)

Vitamin D2

EXPERIMENTAL

Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)

Dietary Supplement: Vitamin D2

Vitamin D3

EXPERIMENTAL

Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)

Dietary Supplement: Vitamin D3

Interventions

Vitamin D2DIETARY_SUPPLEMENT

Ergocalciferol vitamin D2

Vitamin D2
Vitamin D3DIETARY_SUPPLEMENT

Cholecalciferol vitamin D2

Vitamin D3

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • D levels \<30 ng/ml (Vitamin D sufficient) OR \<20 ng/ml (Vitamin D deficient)
  • At least 18 years of age

You may not qualify if:

  • Hypercalcemia
  • Hyperparathyroidism
  • Hyperthyroidism
  • Hypercalciuria
  • Renal disease
  • Intestinal malabsorption any disorder that places the subject at risk for developing hypercalcemia or hypercalciuria during standard vitamin D replacement therapy owing to the presence of underlying dysregulated vitamin D metabolism (e.g., sarcoidosis, TB, etc)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UCLA

Los Angeles, California, 90095, United States

Location

Related Publications (1)

  • Shieh A, Chun RF, Ma C, Witzel S, Meyer B, Rafison B, Swinkels L, Huijs T, Pepkowitz S, Holmquist B, Hewison M, Adams JS. Effects of High-Dose Vitamin D2 Versus D3 on Total and Free 25-Hydroxyvitamin D and Markers of Calcium Balance. J Clin Endocrinol Metab. 2016 Aug;101(8):3070-8. doi: 10.1210/jc.2016-1871. Epub 2016 May 18.

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

ErgocalciferolsCholecalciferol

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • John S Adams, MD

    University of California, Los Angeles

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 2, 2013

First Posted

May 7, 2013

Study Start

August 1, 2010

Primary Completion

February 1, 2020

Study Completion

February 1, 2020

Last Updated

March 3, 2020

Record last verified: 2020-02

Locations